TrialJournal for immunotherapy of cancer2026

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

Jose Luis Perez-Gracia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.